| What are the most important quality of life domains for patients with aplastic anemia and paroxysmal nocturnal hemoglobinuria? |
|
Annals of Hematology |
Aplastic Anemia, Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Hemopoietic stem cell transplantation for infectious mononucleosis-related aplastic anemia |
|
Annals of Hematology |
Aplastic Anemia |
| Health-related quality of life and symptom-specific functional impairment among patients treated with parenterally administered complement inhibitors for paroxysmal nocturnal hemoglobinuria |
|
Annals of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Patient-reported outcomes in patients with paroxysmal nocturnal hemoglobinuria treated with crovalimab and approved C5 inhibitors in the phase III COMMODORE 2 and 1 studies |
|
Annals of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Predictors for improvement in patient-reported outcomes: post hoc analysis of a phase 3 randomized, open-label study of eculizumab and ravulizumab in complement inhibitor-naive patients with paroxysmal nocturnal hemoglobinuria |
|
Annals of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| The prognostic value of serum erythropoietin in patients with lower-risk myelodysplastic syndromes: a review of the literature and expert opinion |
|
Annals of Hematology |
Myelodysplastic Syndromes (MDS) |
| Baseline Clinical Characteristics and Disease Burden in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH): Updated Analysis From the International PNH Registry |
|
Annals of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Effectiveness and safety of tacrolimus with or without eltrombopag, as a part of immunosuppressive treatment of aplastic anemia in adults: a retrospective case series |
|
Annals of Hematology |
Aplastic Anemia |
| Prophylaxis and management of thromboembolism in pnh patients: an italian survey |
|
Annals of Hematology & Oncology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Iron Chelation in Transfusion-Dependent Patients With Low- to Intermediate-1-Risk Myelodysplastic Syndromes |
|
Annals of internal medicine |
Myelodysplastic Syndromes (MDS) |
